Estudo randomizado | Atezolizumabe com terapia neoadjuvante antirreceptor 2 do fator de crescimento epidérmico humano e quimioterapia no câncer de mama inicial positivo para receptor 2 do fator de crescimento epidérmico humano.

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial – Journal of Clinical Oncology

Comentário: Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer – OncLive

Comentário no Twitter

Presented at #ESMO VP6, IMpassion050 is now published on JCO. The addition of atezo to neoadjuvant ddAC-T+HP doesn’t increase pCR rates in HER2+ EBC, neither in ITT (left) nor PD-L1+ (right). Significant increase in toxicity with atezo, including 5 deaths.https://t.co/fL6mEjKTTS pic.twitter.com/2fYStkh8Zt

— Paolo Tarantino (@PTarantinoMD) June 28, 2022